International biotechnology company Percheron Therapeutics (ASX: PER) has been granted a key patent in the United States for its lead drug candidate, ATL1102.
The patent filing includes key data describing the activity of ATL1102 in this disease, including from a phase IIa study that was recently published in a peer-reviewed scientific journal.
The granting of the patent by the US Patent and Trademark Office precludes other companies from commercialising ATL1102 in Duchenne muscular dystrophy in the United States until at least 2039. The patent may thereafter be eligible for a patent term extension of up to five years.
"It is very gratifying to see this patent granted,” Percheron CEO, Dr James Garner, said.
“The company has put a persuasive body of evidence to patent agencies in key territories, who have reviewed it in detail. The granting of a patent such as this substantially increases the value of ATL1102, and will no doubt be enormously helpful in our future discussions with partners and investors.”
Percheron reports similar applications remain under evaluation by patent authorities in other key territories.
ATL1102 is currently the subject of an ongoing international phase IIb clinical trial in non-ambulant boys with Duchenne muscular dystrophy. Data is expected in 2H CY2024.
